Research projects
Cima Universidad de Navarra
-
Non-Coding RNA and Cancer GenomeActive
Using RNA biology to identify vulnerabilities in ovarian cancer
Cima Principal Investigator: Maite Huarte -
Oncogenes and Effector TargetsActive
Characterization of the combined pharmacological inhibition of KRAS and JAK2 in immunocompetent models of pancreatic cancer
Cima Principal Investigator: Julio José Jiménez AlonsoFunder: Asociación Española contra el CáncerAward year 2024 -
RNA and SenescenceActive
RYC2022-036819-I M. MONTES
Cima Principal Investigator: Marta Montes ResanoFunder: Asociación Española contra el CáncerAward year 2023 -
Gene Therapy in Parkinson's DiseaseActive
Calbindin gene therapy for Parkinson's disease
Cima Principal Investigator: José Luis Lanciego PérezFunder: Asociación Española contra el Cáncer -
Enable TechnologiesActive
Precision tools for immunotherapy of hematological malignancies: development of a synthetic library of nanobodies for therapies based on ADCs and CAR-T cells
Cima Principal Investigator: Antonio Pineda LucenaFunder: Asociación Española contra el Cáncer -
Non-Coding RNA and Cancer GenomeActive
Non-coding RNA in the coordination of genome integrity (RNAGEST) (RANGERS)
Cima Principal Investigator: Maite HuarteFunder: Asociación Española contra el Cáncer -
Combination Strategies for Translational ImmunotherapyActive
Synergistic combinations in cancer immunotherapy of agonist agents that interfere with pro-tumor inflammation
Cima Principal Investigator: Ignacio Melero BermejoFunder: Asociación Española contra el Cáncer -
Dynamics of the antitumor immune responseActive
New therapeutic strategies to increase the recruitment of immune cells in tumors (RECRUITHER)
Cima Principal Investigator: Álvaro Teijeira SánchezFunder: Asociación Española contra el Cáncer -
Machine Learning in BiomedicineActive
Deep Explanatory Learning to find personalized therapies against drug resistance in deadly cancers
Cima Principal Investigator: Mikel HernáezFunder: Asociación Española contra el Cáncer -
Oncogenes and Effector TargetsActive
Exploiting the VULNErabilities generated by the pharmacological inhibition of kRAS for the development of combined therapeutic strategies
Cima Principal Investigator: Silvestre Vicent CambraFunder: Asociación Española contra el Cáncer